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ABSTRACT 
 
VraSR two-component system in S. aureus senses bacterial cell wall damage caused 
by antibiotics (vancomycin or β-lactams) and regulates a set of genes. We have undertaken 
the study of the role of certain amino acids in the function of VraR, which undergo 
mutation in clinical S. aureus resistant strains and analyzed their effects on the VraSR 
signal transduction mechanism. In particular, we have looked at the role of Met-13 in VraR 
phosphorylation induced activation. M13A failure to be activated by phosphorylation 
resulted in a weaker binding to DNA. Moreover, we investigated VraR E59D, S164P, 
A113V, and S164A binding activity to the PvraSR by DNase-I footprinting. Finally, in vivo 
studies on the effects of substitutions of the above residues on the mRNA level of a number 
of VraSR regulon genes (fmtA, pbp2, and sgtb) provide insights as to how substitutions at 
certain positions may be beneficial to the S. aureus resistance to antibiotics. 
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1 CHAPTER ONE: S. AUREUS TWO-COMPONENT SYSTEM 
 
1.1 Staphylococcus aureus properties and pathogenicity 
Staphylococcus aureus (S. aureus), a Micrococcaceae family member is a gram-
positive bacterium, which can appear as grape-shaped clusters under the microscope. S. 
aureus has round, large, and golden-yellow colonies (Ryan K.J, et al, 2004; Lowy F.D, 
1998). S. aureus cell wall is a vital structural element in stress-bearing and shape-
maintaining. It consists of cross-linked peptidoglycan (PG) chains via peptide bridges. The 
main unit of PG is a disaccharide-pentapeptide such as N- acetylglucosamine and N-
acetylmuramic that is connected by glycosidic bonds. This pentapeptide is covalently 
connected to the lactyl group of the muramic acid such that its composition is varied among 
bacteria. In both Bacillus subtilis (B. subtilis) and Escherichia coli (E. coli), the dibasic 
amino acid of the peptide is meso-diamoinopimelic acid, whereas in S. aureus it is L- lysine, 
to which a penta-glycine linked bridge is bound (Figure 1.1). PG chains have a maximum of 
20 to 26 disaccharide units making a thick cell wall also containing teichoic acid and 
teichuronic acid as well as some proteins (Scheffers D, et al, 2005).  
S. aureus is normally found as a commensal bacterium associated with skin and 
mucosal membranes, especially in the nasal passages of healthy individuals. However, it can 
act as a human pathogen by colonizing in the anterior nares sites. Patients with S. aureus 
infections are normally infected with a similar strain as their commensal. S. aureus is one of 
the major sources of hospital and community-acquired infections, due to typically 
compromised immune system in patients (Diekema D, et al., 2001; Plata K, et al, 2009). 
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Nosocomial S. aureus infections affect the skin, bloodstream, and respiratory tract. It can be 
a cause of bacteremia, pneumonia and sepsis, and even deep-rooted infections such as 
endocarditis and osteomyelitis (Foster TJ, 1991; Schito G, 2006). Moreover, S. aureus is 
often responsible for toxin-mediated diseases such as toxic shock syndrome, staphylococcal 
foodborne disease (SFD), and scalded skin syndrome (Lindsay J.A, & Holden M.T, 2004).       
                
Figure 1. 1 Peptidoglycan basic unit structure is taken from Scheffers and G. Pinho, 
(2005). 
Disaccharide-pentapeptide is the basic unit of the S. aureus cell wall peptidoglycan. 
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1.2 Antibiotic resistance in S. aureus  
1.2.1 Penicillin-resistant S. aureus                                                               
The origin of antibiotics and antibiotic-resistance in S. aureus goes back to 1941, 
when penicillin was first introduced to clinical practice. Penicillin was the first antibiotic, 
produced by penicillium, a mold, which was discovered by a Scottish scientist, Alexander 
Fleming in 1928 (Grundmann H, 2006). In 1942, two years after penicillin introduction, the 
first series of penicillin-resistant staphylococci (PRSA) were recognized in hospitals and 
societies (Rammelkamp C.H, & Maxon T, 1942). The penicillin resistance in S. aureus is 
due to the blaZ gene function that is encoding β-lactamase. In the presence of β-lactam 
antibiotic, this enzyme breaks the structural ring of the antibiotic leading to its inactivation. 
There are two nearby regulatory genes, blaI (repressor) and blaRI (anti-repressor), which 
control the blaZ gene (Kernodle D.S, 2000). BlaRI, as a protease, hydrolyzes itself and BlaI 
allows blaZ to produce enzymes in the case of any exposure to β-lactams (Gregory P.D, et 
al, 1997; Zhang H.Z, 2001) (Figure1.2). 
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Figure 1. 2 Induction of staphylococcal β-lactamase synthesis in the presence of 
penicillin that is taken from Lowy FD. (2003).  
I) In the presence of penicillin, BlaI binding to the operator region, represses blaZ and blaRI-
blaI transcription. II) Binding of penicillin to the BlaR1 stimulates its activation. III-IV) 
Active BlaRI cleaves BlaI by BlaR2 assistance and lets the transcription to start. V-VII) β-
lactamase encoded by blaZ, breaks the β-lactam ring of penicillin and causing its 
inactivation. 
 
 
By the late 1960s, more than 60% of the S. aureus strains, mostly in hospitals, had 
acquired penicillin resistance, and 90% of S. aureus strains showed resistance through the 
production of β-lactamase (Lowy F.D, 2003). Eventually, scientists started an intense race to 
win the battle between resistant bacteria and significant antibiotic discovery.  
1.2.2 Methicillin-resistant S. aureus (MRSA) 
In 1959, methicillin, a semi-synthetic penicillin, was discovered to overcome the 
inactivation of penicillin by β-lactamase (Lowy F.D, 2003). Initially, methicillin and other β-
lactams were successful in treating penicillin-resistant S. aureus. However, the extensive 
usage of methicillin was followed by reports of methicillin-resistant S. aureus (MRSA) 
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isolates as early as 1961. In 1970 MRSA had become the major cause of nosocomial 
infections globally and was termed “super bug.”  
The mechanism leading to methicillin resistance was finally identified in 1981. 
MRSA arose because of the acquisition of the mecA gene from Staphylococcus sciuri7 
(Stapleton P.D, & Taylor P.W, 2002). The 2.1-kb mecA codes for penicillin-binding protein 
2a (PBP2a) is located on a genetic element, Staphylococcal Cassette Chromosome mec 
(SCCmec). In the presence of the β-lactam antibiotic, PBP2a affinity, which is responsible 
for the last step of cell wall peptidoglycan synthesis, is reduced but the cell wall biosynthesis 
continues developing. In this case, methicillin cannot bind to the target PBP (Ito T, et al., 
2003). 
The high occurrence of MRSA in hospitals from 1997 to 1999 was noted 66.8% in 
Japan, 40.4% in South America, 34.2% in Latin America and 33.4% and 26.3% in the USA 
and Europe. Since the emergence of MRSA, the treatment of choice was the glycopeptide 
vancomycin (Bell J.M, et al., 2002; Diekema D, et al., 2001).   
1.2.3 Vancomycin-resistant S. aureus (VRSA) 
The early 1990s showed a noticeable increase in vancomycin use in United States 
due to the growing numbers of infections with staphylococci strains in health care 
institutions. As a consequence, MRSA became resistant to the only effective antibiotic, 
vancomycin. The first strain of S. aureus with reduced susceptibility to vancomycin emerged 
in Japan in 1997 (Gaddad S, et al, 2011). Later, in 2002, vancomycin-resistant S. aureus 
(VRSA) isolates were found in the USA. No antibiotic could solely overcome their 
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resistance ability (Enright M, 2003). Analyzing the MRSA isolates with reduced 
susceptibility to vancomycin revealed a reduction in peptidoglycan cross-linking leading to 
high exposure of D-Ala-D-Ala residues. The reduced amount of L-glutamine responsible for 
amidation of D-glutamate in the pentapeptide bridge is the result of altered cross-linking 
(Walsh T.R, & Howe R.A., 2002). Therefore, more D-Ala-D-ala is produced to trap the 
applied vancomycin. Consequently, vancomycin segregates, causing a reduction of the 
antibiotic amount reaching to the sites of the cell wall biosynthesis that results in a thickened 
cell wall (Cui L, et al, 2000).  
Another form of vancomycin resistance (complete vancomycin-resistant strains) is 
mainly due to the acquisition of foreign vanA operon. Thus, the vanA gene makes particular 
changes in the cell wall precursor terminal peptide of D-Ala-D-Ala to D-Ala-D-lac (Lowy 
F.D, 2003). The new peptide has a significant low affinity for vancomycin. Hence, future 
therapies and investigations may be needed to overcome this function (Figure 1.3). 
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Figure 1. 3 Vancomycin resistance mechanisms in S. aureus, that is taken from Lowy 
F.D. (2003).  
Upon vanA operon acquisition by S. aureus, the terminal peptide of the cell wall precursor is 
changed from D-Ala-D-Ala to D-Ala-D-Lac leads to vancomycin resistance by causing 
reduced affinity for Vancomycin. 
 
1.3 Two component regulatory systems (TCRSs) 
According to the bacterial antibiotic resistance history, this obstacle has been 
considered by numerous scientists who have completed research in an effort to discover a 
solution. One target, which has recently attracted researchers’ attention, is the “two 
component systems” (TCSs) existing in Eubacteria, Archaea, and Eukarya (Koretke K, et al., 
2000). These organisms utilize sensing and signaling transduction systems to adapt to 
environmental stimuli. TCSs are composed of a homodimeric histidine kinase (HK) and a 
response regulator (RR); HKs sense external stress and transmit the related information to 
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the RR in a phosphorylation process. In this phosphorelay pathway, the HK is 
phosphorylated on a conserved histidine residue, which then transfers its phosphoryl group 
to the aspartic acid of the RR. In general, many phosphorylated RRs then bind to the 
upstream region of pathogenic genes and regulate their expression. Sometimes HK also 
dephosphorylate the phosphorylated RR due to its phophotranferase ability. Comparing the 
difference between phosphorylation and dephosphorylation determines the RR’s 
phosphorylation state regulating gene expression (Stock AM, 2009), (Figure 1.4). TCSs 
could represent novel targets for the development of antibacterial agents, in particular due to 
their absence in animals and humans (Gotoh Y, et al., 2010). TCSs have been involved in 
antibiotic resistance, such as resistance to bacitracin in B.subtilis-LiaSR- (Mascher T, et al., 
2003) and vancomycin in Enterococcus faecium –VanSR- (Wright G.D, et al., 1993) or S. 
aureus (VraSR); both, bacitracin and vancomycin are cell wall synthesis inhibitors. 
  9 
                  
 
Figure 1. 4 A schematic diagram shows a simple two-component system is taken from 
Jensen R.B, et al. (2002).  
The TCS consists of a histidine kinase (HK) and a response regulator (RR).  Upon bacteria 
cell wall damage, HK senses the environment signal by activating its autokinase domain. As 
a result, the His residue of HK receive a phosphoryl group from ATP and then transfers it to 
the RR Asp residue. The active RR regulates the expression of some gene by binding to its 
promoter. 
 
1.3.1 VraSR Two-component system 
S. aureus has 16 pairs of two-component system, one of which is the VraSR system. 
The VraSR system is unique from other TCSs in that it controls the S. aureus reaction to 
inhibitors of “early and late steps” in cell wall peptidoglycan biosynthesis (Utaida S, 2003).  
Briefly, the main constituent of the bacterial cell wall is peptidoglycan as its 
synthesis takes place in three main steps at different locations in the cell. First, the sugar-
linked precursor, UDP-N-acetylmuramyl (UDP-Mur-NAc)-pentapeptide and UDP-N-
acetylglucosamine (UDP-GlcNAc) are produced in the cytoplasm. Second, lipid I is formed 
at the cytoplasm membrane by linking the UDP-Mur-NAc- pentapeptide to the transport 
lipid, called undecaprenyl pyrophosphate. Lipid II is produced when GlcNAc from UDP-
GlcNAc is added to the lipid I. The pentapeptide cross bridges are added to the third amino 
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acid of the lipid II. Then, lipid II is transferred to the external side of the cell membrane by a 
protein assistant. Moreover, it is incorporated into nascent peptidoglycan by penicillin-
binding proteins (PBPs). Lastly, PBPs catalysis reactions such as transglycosylation and 
transpetidation that lead to the glycan polymerization (Pinho M.G, et al., 2013).  
Knowing the information above, it is interesting to discover more about this system 
and restoring susceptibility to strains that are resistant to antimicrobials. VraSR regulates the 
expression of more than 40 genes in S. aureus (Kuroda M, 2003), which are associated with 
peptidoglycan biosynthesis in response to cell wall inhibitors (Fan X, et al, 2007).  Some of 
these genes, murz, pbpb2, sgtb, and fmtA and so many others, are clearly under the direct 
control of the VraSR system in the presence of oxacillin, vancomycin, and other cell-wall 
inhibitors (Sengupta M, et al., 2012). It has been demonstrated that murZ encodes Uridine 
diphospohate N-acetylglucosamine-1 carboxylvinyl transferase 2; pbpB encodes penicillin-
binding protein (PBP) 2; sgtB encodes a putative monofunctional glucosyltransferase; and 
FmtA, which is an autolysis-methicillin-resistance protein, is encoded by fmtA gene (Utaida 
S, et. al., 2003).  
1.3.2 Cell-wall associated genes regulation under vraSR promoter 
As it has been confirmed at Dr. Sengupta Laboratory (2012), several genes, which 
are associated in cell wall biosynthesis, are under the vraSR regulatory mechanism. 
Understanding their functions could help us to identify any possible connections with the 
vraSR regulatory system. 
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The SgtB or MGT roles are important in terms of cell-wall stress conditions, 
especially in the final stage of peptidoglycan biosynthesis (Sengupta M, et al., 2012). Two 
types of enzymes are required to assemble peptidoglycan polymers: peptidoglycan 
glycosyltransferases (PGTs) and transpeptidase (TPs). S. aureus comprises two 
monofunctional PGTs such as SgtA and SgtB and one bifunctional PGT (PBP2), (Rebets Y, 
et al., 2014). In the absence of PBP2, SgtB is more important than SgtA as it can replace 
transglycolase activity of PBP2. As a result, SgtB is essential in S. aureus viability (Reed P, 
et al., 2011). 
PBP2, the MRSA native protein, contains an N-terminal PTG domain and a C-
terminal TP domain that accelerate carbohydrate chains cross-linking in cell wall 
biosynthesis (Pinho M, et al. 2001, Rebets Y, et al., 2014) According to Boyle-Varvra S. 
(2003), pbp2 transcript levels increases by oxacillin and vancomycin inductions. Thus, the 
pbp2 expression level could be upregulated by the VraSR (Gardete S, et al., 2006).  
FmtA, a member of the VraSR regulon, is a low-affinity penicillin-binding protein 
contributing to peptidoglycan biosynthesis under cell wall stress in S. aureus. Active fmtA 
increases the level of peptidoglycan cross-linking (Zhao Y, et al., 2012). The fmtA gene was 
shown to be upregulated by cell wall-antibiotic stress (Sengupta M, et al . ,  2012). 
Accordingly, studies indicate that the VraSR system plays a critical role in preserving the 
“integrity” of the cell wall peptidoglycan and modulating t h e  S. aureus response to cell 
wall damage, quite similar to an antibiotic resistance mechanism (Belcheva A, & Golemi-
Kotra D, 2008).   
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1.3.3 VraS, the histidine kinase 
HKs normally are membrane bound proteins that contain an N-terminal 
transmembrane sensing domain and a cytoplasmic C-terminal domain known as kinase core. 
The specific structural features of the HK family consist of a dimerization domain (DHp) 
and an ATP/ADP- binding or catalytic domain (Casino P, et al., 2010). Members of the HK 
family vary in size from <40 kDa to >200 kDa; the largest HKs are composed of five or six 
unique domains. vraS is a vancomycin-resistance-associated gene with homology to the 
histidine kinase family (Kuroda et al., 2000), located immediately upstream of vraR, a 
response-regulator homologue (Utaida S, et al., 2003). Analysis of the VraS amino acid 
sequence indicates that this typical HK protein is composed of an N-terminal transmembrane 
domain and a C-terminal conserved HK core (Belcheva A., & Golemi-Kotra, D, 2008). The 
N-terminal transmembrane domain of VraS consists of two membrane areas that are 
connected through a periplasmic connector. The conserved HK core of VraS contains the 
dimerization and histidine phosphotransfer (DHp) domain, which includes the conserved His 
residue, and the catalytic (CA) or ATP-binding domain (Gross R, 2012), (Figure 1.5). 
1.3.4 Structural characteristics of VraR response regulator 
A prototypical response regulator contains an N-terminal receiver (REC) domain 
connected to a variable effector domain by a flexible linker (Stock AM. et al., 2009). N-
terminal domains have highly homologous structures consisting of an α-β construction with a 
central five-stranded parallel β-sheet surrounded by five α-helices. β-strands and the α-
helices are connected by the loops arranged around the active-site aspartic acid that is 
  13 
located at the end or top of the protein. Normally, the active site is composed of three Asp 
residues; the phosphorylatable Asp at the end of strand β3; and two Asp residues (or a Glu 
sometimes) are bordering the β1-α1 loop. The last two mentioned residues help to form an 
Asp-binding pocket that accepts a divalent metal ion prior to phosphorylation. (Bobay B.G 
et.al., 2012).  
In fact, most RRs are known as transcription regulators and are categorized into three 
sub-families based on their effector (REC) domain homology: the OmpR/PhoB winged helix 
binding domain, “the NarL/FixJ four-helix bundle domain, and the NtrC-ATPase-coupled 
transcription factors” (Robinson V.L, et al., 2000). According to the homologous RR NarL, 
VraR is a typical response regulator protein that has two domains composed of a conserved 
N-terminal receiver domain (REC) and a C-terminal DNA-binding or effector domain (ED) 
(Figure 1.5). The REC domain possesses a distinctive (αβ)5 fold and is 117 bp in length (Liu 
Y, et al., 2009). The VraR effector domain has a four-helix structure that individually has a 
specific role in the VraR mediated genetic regulation. H1 (H7) is involved in activation, H2 
(H8) is related to scaffolding, H3 (H9) aids in the DNA recognition, and H4 (H10) is 
involved in dimerization process (Donaldson L.W, 2008).  
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Figure 1. 5 The schematic demonstration of VraSR two component system is taken 
from Belcheva A., & Golemi-Kotra D. (2008)  
The sensor HK, VraS and the response regulaor, VraR are shown with their amino acid 
positions on their domains. Phosphorelay process is also shown, starting from VraS 
autophosphorylation and transferring to the VraR and ending up to the VraR dimerization 
and DNA binding.H: histidine box; ATP: ATP binding domain; R: REC domain; ED: 
effector domain  
 
1.3.5 VraSR signal transduction pathway 
Both prokaryotic and eukaryotic HKs contain the same basic signaling components, 
namely a diverse sensing domain and a highly conserved kinase core that has a unique fold 
(Jung K, et al., 2012).  HKs undergo autophosphorylation in kinase core. Stimuli in different 
reconstituted full-length HKs can either enhance or inhibit kinase activities. To facilitate the 
understanding of HK regulation in vivo, additional methods are performed using 32P labeling 
or a specific phosphate binding tag. As well as kinase activity, many HKs have phosphatase 
activity toward their cognate phosphorylated RRs. The DHp domain possesses the 
phosphatase activity that is due to the dimerization and catalytic domain interactions. As the 
RR phosphorylation level eventually determines the TCS pathways’ output response, the 
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balanced regulation between the kinase and phosphatase activities of the HKs leads to the 
signal-induced adjustment of RR phosphorylation (Gao R, & Stock A.M, 2009). The RR-P 
dephosphorylation is not only the reversed RR-phosphorylation since it is not absolutely 
dependent on the HK. The phosphorylation and dephosphorylation are catalyzed by both HK 
and RR. Both of these proteins contribute in to the formation of an active site that facilitates 
the processes. In the case of phosphorylation, structural studies carried out with the HK839-
RR-468 complex, show that the phosphor-acceptor Asp residue of RR is aligned with the 
phosphor-donor His residue of HK, favoring phosphoryl group transfer reactions. This 
alignment is facilitated by binding of the RR to the helical stem of one HK subunit through 
interactions of helix-α1 of DHp domain with the first helix and the last loop of RR (Casino 
P, et al., 2009). In the case of dephosphorylation, a water molecule is needed to be activated 
by His residue of DHp in order to attack the phosphorus atom of the Asp-P species. 
However, structural studies show that the HK-RR complex discussed above forms active site 
that supports the dephosphorylation mechanism (Casino P, et al., 2010). 
The signal transduction pathway by VraSR is proposed to happen as follows. Upon 
cell wall damage, VraS monitors extracellular stimuli and modulates the activities by 
sending input signals to the sensing domain. Recent studies on YvqF (VraT) shed new light 
on the VraSR regulatory system process, which is shown in VISA-clinical isolates, and 
appears to detect cell-wall damage. It is a transmembrane protein and is located immediately 
upstream of vraS. The S. aureus YvqF demonstrates amino acid similarity to B. subtilis-
LiaF, acting as an inhibitory element on LiaR expression, which is also VraR orthologous 
  16 
(Boyle-Varvara S., et al., 2012).  
The phosphorylation process is initiated by transferring a phosphoryl group from 
ATP to a conserved His residue of the VraS. Subsequently, the phosphoryl group is 
transferred from the phospho-His residue to a conserved Asp-55 of VraR while being 
catalyzed by the regulatory domain. Finally, the phosphoryl group is transferred from the 
phospho-Asp residue to a water molecule via a hydrolysis reaction (Stock A.M, 2009; Laub 
M.T, 2011). The phosphotransfer reaction showed that this event is faster than VraS 
autophosphorylation in vitro; and about 70% of the VraR phosphorylation is happening 
within 30 seconds. This result, along with the fast kinetics of VraS autophosphorylation, 
proposed that the VraSR complex could contribute in transducing cell wall stress in vivo 
rapidly (Belcheva A, & Golemi-Kotra D, 2008). 
Asp-55 phosphorylation also builds a conformation in the VraR REC domain and 
stimulates its dimerization by dislocating the inter-domain interface to form a dimer on the 
DNA-binding domain. X-ray crystal structure analysis reveals a considerable remodeling of 
the REC domain, creating a deep hydrophobic surface known as a “hydrophobic pocket.” 
The hydrophobic surface is positioned between α1 and α5 helices and is responsible for VraR 
dimerization. During VraR dimerization, Metionine-13 (M13) residue docks into this 
“pocket.” Correspondingly, an M13 mutation to Glutamic acid (D) prevents VraR from 
forming the dimer without any significant changes on the overall fold and catalytic activity 
(Leonard P.G, et al., 2013). This fact showed the importance of this residue in VraR 
dimerization. In the active VraR structure Thr83 and Tyr102, known as the switch residues, 
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adopt a distinctive active conformation, with the –OH- group of Thr83 and the phenol ring of 
Tyr102 establishing direct hydrogen bonds with beryllofluoride and the backbone carbonyl 
of Phe85.  
1.3.6 VraR DNA binding activity 
The VraR DNA-binding domain consists of four α-helixes (Leu148 to Gln209). The 
H2 (H8) and H3 (H9) form a classical helix-turn-helix (HTH) (Donaldson L.W, 2008). HTH 
is a fundamental structural motif containing two α-helixes connected by a short strand of 
amino acid that exists in proteins and can bind to DNA. Ultimately the HTH forms dimers in 
the active VraR protein after phosphorylation process. Then, VraR binds to specific regions 
of the VraSR promoter (PVraSR). According to the previous predictions, helix H9 (residues 
Ile176 to Leu190) is the DNA-recognition that slots into the DNA major groove (Liu Y.H, et 
al., 2009).  Nevertheless, the DNA binding site of VraR-P is the H8–turn–H9 motif in the C-
terminal domain. The DNA binding domains create dimers in the active VraR protein, and 
the hydrophobic face of α10 is burying certain protein surface area with the C-terminal end 
of α7 in the dimerization interface (Leonard P.G, et al., 2013).  
The DNase I footprinting analysis indicates that VraR binds to three distinct sites 
which are located on positions -76 (R3), -60 (R1) and -35 (R2) depending on its 
phosphorylation state (Belcheva A, et al., 2009). R1 is demonstrated to be a phosphorylation 
independent and high-affinity binding site, which serves as a means of recruitment of VraR 
to its promoter under normal growth conditions and gene expression regulation. On the other 
hand, R2 is known as low-affinity and phosphorylation-dependent site, which gets occupied 
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by phosphorylated VraR (VraR-P) under cell wall antibiotic stress as a result of VraSR 
operon upregulation (Belcheva A., et al., 2011).  
1.3.7 vraR mutants in VISA strains 
Recently it has been proposed that genetic alterations in TCS genes such as vraSR, 
graSR, etc., have an effective influence on glycopeptide-resistance phenotype (Kuroda M, et 
al., 2003; Meehl et al., 2007; Neoh et al., 2008). Another study also demonstrated that the 
evolution of VISA from VSSA strains during “persistent infection” related to the failed 
vancomycin treatment, could be due to a single base substitution (Kato Y, et al., 2010). 
Accordingly, the first study on the point mutations between clinical VISA and VSSA, and 
their amino acid changes has commenced. In this research, sequences of vraSR, graSR and 
many more were investigated from VISA and VSSA strains collected from hospitals. The 
analysis of the prevalence of amino acid substitutions in the VraR such as, E59D, A113V 
and S164P, demonstrated that the corresponding mutations in vraR were associated with the 
emergence of a VISA strain from the VSSA strain after constant exposure to vancomycin. 
The occurrence of the above amino acid changes was different in VISA and VSSA strains. 
Although the prevalence of mutations in vraR of VSSA strains was lower than that of 
VISAs, the number of VISA strains bearing mutations (including positions other than those 
above) was high compared with the number of VSSA respectively. Furthermore, the above 
mutations were demonstrated to be involved in glycopeptide resistance in VISA (Yoo J.I, et 
al., 2013). As a matter of fact, our primary lab interest was to study VraR variants in the 
signal transduction pathway by VraSR.  
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2 CHAPTER TWO: IN VITRO AND IN VIVO INVESTIGATION OF 
VraR MUTATION ON ITS REPONSE TO CELL WALL DAMAGE 
 
2.1 Introduction 
The main aspect of this research is to focus on VraR protein as on of the major 
targets for antibiotic resistant mechanism (Gao R, & Stock A.M, 2009). As it has been 
reported that TCRS gene alterations contribute to the glycopeptide-resistance phenotype 
like in the vraSR genes (Yoo J.I, et al., 2013), various point mutations, in either clinical or 
lab strains were tested. We decided to examine the point mutations in vraR that lead to the 
following amino acid substitutions, E59D, S164P, and A113V, which were identified in the 
clinical strains due to their strong relationship with the glycopeptide resistance 
(vancomycin). Moreover, S164A and M13A from previous studies are also chosen to study 
(Figure 2.1). S164A, adopted from S164P was used to analyze the difference of single point 
mutation from proline to alanine and possible changes that may occur. Also, Methionine-13 
(Met-13) positioned on the α1-helix of VraR, w h i c h  was shown by crystallography to 
be involved in dimerization of VraR upon phosphorylation (Stock A.M, 2013), is tested 
for the potential consequences. Initially, the phosphorylation and dimerization ability of 
VraR mutants were examined in order to compare with the VraR wild type. This was 
followed by analysis of protein-DNA interactions and possible effects of Oxacillin on 
VraR regulon genes such as fmtA, pbp2, and sgtb in vivo. Understanding the VraR signal 
transduction pathway is important in order to know this protein functions in the stress 
conditions. If we can comprehend its structural transitions and how the signal is 
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disseminated to the DNA binding domain, we can design pharmaceuticals to eliminate 
antibiotic resistance progression by targeting VraR protein. 
 
 
 
 
Figure 2. 1 The schematic presentation of VraR and amino acid substitutes location 
M13, E59, and A113 (in red) are located at the N-terminal domain and S164 (in red) is 
located at the C-terminal domain (Numbers at the C-terminal domain are representing the 
number of alpha-helixes). 
 
 
 
 
 
 
N-	terminal 
C-	terminal 
7 8 
9 10 
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2.2 Materials and Methods 
2.2.1 Chemicals 
Chemicals, growth media, and antibiotics were purchased from Thermo-Fisher 
(Whitby, Canada) or Sigma (Oakville, Canada), unless otherwise stated. Escherichia coli 
strains, Nova-Blue and BL21 (DE3), and other expression plasmids were purchased from 
EMD4 Biosciences (New Jersey, USA). All the primers were purchased from Sigma 
(Oakville, Canada). Chromatography columns and media were bought from GE-Healthcare 
(Mississauga, ON, CA). Radioactive  [γ-32P]-ATP was purchased from Perkin Elmer (Life 
and Analytical Sciences, Waltham, MA, USA). 
2.2.2 Generation of VraR and its variants 
The vraR and its variants (VraR M13A, VraR S164P, VraR S164A, and A113V) 
were cloned into the pET26b vector and transformed into E. coli BL21 (DE3) by other 
co-workers in Dr. Golemi-Kotra’s Lab. The Glu-59 residue of VraR (encoded by GAA) 
was mutated to Asp (encoded by GAC) by performing a mutagenic polymerase chain 
reaction (PCR) using pfu Turbo
TM DNA polymerase, and the designed primers (Table 
2.1). To digest only the methylated template DNA (pET26b::VraR) construct , DpnI 
endonuclease digestion was done on the PCR product, and the resulting mixture was used 
to transform E.coli NovaBlue competent cells. At the end, the final construct was 
transformed into E.coli BL21 (DE3). The Centre for Applied genomics (TCAG) facilities 
(Sick Kid’s Hospital) confirmed the mutation of the E59D by performing DNA sequencing 
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analysis (Raw sequencing data are in Appendix A, Figure A1). 
 
 
 
 
 
2.2.3 Production and purification of wild type/Mutant proteins 
VraR wild type, its variants and VraS protein purification were carried out as 
described by Anthoneta Belcheva (2008). 
2.2.4 Circular Dichroism (CD) spectroscopy and Thermal melting of VraR 
CD measurement of the target protein was carried out by preparing a protein 
solution of 10 µM in an equilibration buffer (20mM Tris, 5mM MgCl2, pH 7.0). The 
CD spectrum was recorded from 200 to 260 nm using a Jasco J-810 instrument (0.1 cm 
path length cuvette). To investigate the effect of the mutation in the overall structure of 
Table 2. 1 primers designed to generate VraR E59D mutant.  
                 Italic bases represent the mutated codon. 
 
Primer Name 
 
Primer Sequence (5’-3’) 
VraR E59D FW 
 
  GATTTACTTATGGACGACATGGATGGTG 
VraR E59D Rev 
 
  CACCATCCATGTCGTCCATAAGTAAATC 
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the protein, the thermal melting process of the protein was carried out by monitoring the 
effect at 222 nm between 20°C-100°C using the Jasco J-810 instrument. 
2.2.5 Phosphorylation of VraR by Lithium potassium acetyl phosphate 
Protein solutions of VraR at 10 µM and 20 µM in the phosphorylation buffer (1XPB 
50 mM Tris, 50 mM KCL, 20 mM MgCl2, 4 °C, pH 7.4) were supplemented by 50 mM 
acetyl phosphate and incubated for 1h at 37 °C to facilitate phosphorylation of VraR or its 
variants. The sample could be tested for Phos-tagTM gel and Native-PAGE gel 
electrophoresis for the following purposes. 
2.2.5.1 Phos-tagTM gel electrophoresis 
Quantification of VraR phosphorylation was investigated using SDS-PAGE 
supplemented with a Phos-tag
TM affinity chemical. The gel consist of a separating gel 
containing 10% Acrylamide, Tris-Cl, pH 8.8, 10% SDS, 10% APS, 100 mM MnCl2, 
TEMED and 20mM phos-tag, and the same stacking gel as SDS gel.  SDS stacking gel i s  
c o m p o s e d  o f  30% Acrylamide, Tris-HCl 0.5mM pH 8.8, 10% SDS, 10% APS, 
 TEMED, dd-H2O. Phosphorylation quantification was done by Image-J software. 
2.2.5.2 Native- PAGE gel electrophoresis 
Dimerization abilities of VraR and its variants upon phosphorylation were 
examined by Native-PAGE. Proteins with different concentrations of 10 µM, 20 µM, and 
30 µM were phosphorylated by 50  mM acetyl phosphate, and were loaded on 10% 
Native gel at 4°C after 1h incubation (37°C). Native-PAGE gel is the same as SDS gel  
but  lacks SDS. SDS-PAGE gel consists of a  separating and a stacking gel (shown at the 
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phos-tagTM section) that in separating gel, 1.5mM Tris-HCL is used. Native running buffer 
contains 25 mM Tris and 192 mM Glycine was used to run the gel with. 
2.2.6 In vitro phosphorylation of VraR by VraS-P 
VraS (20 µM) phosphorylation was started by radioactive ATP (ϒ-32P, 
3000Ci/mmol) and phosphorylation buffer (1XPB: 50 mM Tris, 50 mM KCl, 5 mM MgCl2, 
10 mM CaCl2), and followed by VraR phosphorylation. The unreacted ATP was removed, 
by using Zeba desalting column after 1 h incubation (RT), and mixed with 20 µM VraR in a 
time order. Quenching the reaction with SDS-loading dye (250mM Tris-Cl, pH6.8, 8% 
SDS, 0.1% Bromophenol blue, 40% glycerol) was done in time intervals for 0, 0.5, 
1,3,5,7,and 10min. For analyzing, 15% SDS gel was used, and then it was visualized by 
exposing it the gel to phosphor screen plus Typhoon Trio instrument (GE-Healthcare).  
2.2.7 DNase-I footprinting assay 
To perform this assay, vraSR promoter (PVraSR ) between -121 to +26 was 
amplified by PCR using the following primers:  
Dir: 5’ ACGAAGCTTGGTCCGATTTTAACGACAAAAATTG-3’ and  
Rev: 5’-TGAAATGACGCATTGATTGTGTTC-3’. Then, the primer of interest (direct 
primer in this case) was 5’-end labeled with T4 polynucleotide kinase (NEB) in the 
presence of ATP (ϒ-32P, 3000Ci/mmol), and then it was re-amplified by  PCR.  The 
following PCR conditions were used: 95 °C for 5 min, 30 cycles of 95 °C for 30 s, 62 °C for 
30 s, 72 °C for 30 s, and a final extension step at 72 °C for 5 min. Targe t32P-labeled 
promoter was purified by QIAquick Gel Extraction Kit (Qiagen) to use as a template with 
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different VraR/VraR-P concentrations (0, 2, 5, 25, and 50 µM) and added to  t he  binding 
reaction mixture (10X Binding buffer: 100 mM Tris pH 7.5, 500 mM KCL, 10 mM DTT, 
supplemented with 10 mM MgCl2, 50% Glycerol, 20 ng/µl Herring sperm DNA). The 
binding reactions were subjected to DNase-I for 2min and then the DNase I stop solution 
(1% SDS, 0.2 M NaCl, 20 mM EDTA, pH 8.0) to digest the DNA. Protein was extracted 
by addition of 1:1 Phenol:Chloroform and precipitated by ethanol. The pellets having the 
DNA were air dried, and resuspended in 10mM formamide, 1mg/ml bromophenol blue, 
and 1mg/ml xylen cyanol, called loading dye. Then it was analyzed by loading samples on 
8% polyacrylamide gel containing urea, and after exposing it to phosphor screen it was 
visualized by Typhoon Trio+ Variable Mode Imager (GE-HealthCare). 
2.2.8 Construction of the pMK4::vraR::PvraSR (-121 to +150) plasmid complementing 
vector 
Previously, PVraSR-462 to +150 variants were constructed by fusing the promoter 
upstream of the lux operon reporter vector pXEN1 (Belcheva A. et al., 2009) and it was 
demonstrated that in the presence of Oxacillin the luminescence signal increased by ~60-
fold for P VraSR::lux. Therefore, we decided to choose a segment of the above region from 
-121 to +150 with respect to the transcription start site to perform the in vivo studies. 
To perform in vivo studies by RT-qPCR and comparing the VraR regulon genes 
expression in different vraR variants, the promoter region of vraSR (P vraSR), spanning 
between -121 to +150  was ligated to the vraR gene and cloned into the pMK-4 vector 
between EcoRI and SalI restriction sites after their extraction independently. For this 
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purpose, the desired regions of the promoter and the vraR gene were amplified using 
designed primers (Table 2.2), and 2.5 U pfu TurboTM DNA polymerase by PCR conditions as 
follow: 95 °C for 5 min, 30 cycles of 95 °C for 30 s, 52 °C for 30 s, 72 °C for 1min, and a 
final extension step at 72 °C for 10 min. Both products were gel purified from 1% agarose 
gel by QIAquick® Gel extraction kit (QIAgen) and digested with BamHI and ligated to each 
other. The resulting product was amplified using similar PCR conditions and after gel 
purification it was mixed with equal volumes of End conversion buffer at 22 °C for 15 min, 
that was provided with the pSTBlue-1 vector (Perfectly Blunt ® Cloning Kit, EMD 
Millipore). Then, it was mixed by T4 DNA ligase (NEB) at 25 °C for 1h. Afterwards, the 
plasmid was transformed into NovaBlue competent cells by heat shock (42 °C, 1min) and 
were grown on X-Gal LB agar supplemented by 50 µg/ml Kanamycin and 80 µM IPTG to 
discriminate between recombinant (white colonies) and non-recombinant cells (blue 
colonies). The pSTBlue-1 extraction was done as mentioned above, and the confirmed 
desired insert was ligated to the pMK-4 vector (following the gen : plasmid ratio: 3:1) 
between EcoRI and SalI restriction sites. Finally t h e  p l a s m i d  w a s  transformed into 
NovaBlue cells by heat shock. Successful cloning and transformation was confirmed by 
DNA sequencing (TCAG facilities). The already confirmed isolated plasmid from NovaBlue 
was introduced to S.aureus RN4220::ΔvraR competent cells by electroporation (2 kV, 2.5 
ms) using Micropulser (Bio-Rad) and were grown on TSB agar supplemented by 10 µg/ml 
chloramphenicol. Glycerol stock of the chosen colonies after plasmid digestion were 
prepared and kept at -80 for further investigations.   
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2.2.8.1 Single-site mutation of pMK4 containing vraR and its promoter 
The already mentioned constructed plasmid was extracted for the single-site mutation 
to generate the vraR mutants (VraR M13A, E59D, S164P, and S164A). Primers containing 
targeted mutations were used to PCR-amplify pMK4 containing vraSR promoter region and 
vraR gene (Table 2.2). The PCR-mutagenesis was performed as follow including a “hot start 
(95°C)” and a “heated lid:on”:  95 °C for 1 min, 16 cycles of 95 °C for 30 s, 55 °C for 1 min, 
68 °C for 10 min and a final extension step at 68 °C for 10 min. The products were digested 
by DpnI and then transformed into NovaBlue competent cells by heat shock. After growing 
cells on LB plates containing 50 µg/ml kanamycin, mutations were confirmed by plasmid 
sequencing (TCAG facilities). Plasmids containing the anticipated mutation were 
transformed into RN4220ΔvraR competent cells by electroporation and spread on Tryptic 
Soy Broth (TSB) agar supplemented by 10 µg/ml Chloramphenicol. Glycerol stocks of the 
confirmed transformation were prepared and kept at -80 for further investigations. 
2.2.9 RNA isolation from S. aureus RN4220 
Overnight seed cultures of each RN4220 cells were prepared in TSB media 
supplemented by 10 µg/ml chloramphenicol. 160 µl of overnight seed cultures were used to 
inoculate 16 ml TSB medium supplemented with 10 µg/ml Chloramphenicol and incubated 
at 37°C (200 rpm) to achieve OD600: 0.4. The cultures were split into two 5-ml in a 15ml 
sterile tube and one was treated with 10 µg/ml oxacillin which was incubated along with the 
control tube –non oxacillin treated tube- at 37 °C for 30 min. 1ml of each tube were mixed 
thoroughly with 2 ml of RNA Bacteria Reagent (Qiagen) for 10 s and incubated 5 min at 
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room temperature (RT) and then centrifuged at 7700rpm for 15min. The resulted pellets 
were resuspended into 180µl TE buffer (30 mM Tris, 1mM EDTA, pH 8.0) and 20 µl of 1.25 
mg/ml lysostaphin following by 30 min incubation at RT. 1 µl proteinase K (NEB) was 
added, and the suspensions were incubated at RT for another 30 min. 700 µl of RLT buffer 
were added and the suspensions were vortexed for 15 s. 2-ml tubes containing 100 µl silica 
glass beads were prepared to transfer our samples in and vortexed 3 times for 20 s, and let 
them rest for 20 sec in between. The samples were spun for 1 min at 13000 rpm, and the 
supernatants were transferred into new tubes which then 470 µl of 100% ethanol were added. 
Each time 720 µl of the samples were loaded onto RNeasy Mini spin columns and 
centrifuged at 13000rpm for 30 s and then washing step was done by 350 µl of RW1 buffer 
and twice by 500 µl RPE buffer. Centrifugation was done for 1 min to eliminate excess 
ethanol and the total RNA was eluted by 50 µl Dnase-Rnase free water. 5 µg of the RNA 
were digested by 2 µl of DNase-I (2000U) for 20min at 37°C that inactivated afterward by 
0.5 M EDTA for 10 min at 75°C. 
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Table 2. 2 primers designed to generate pMk4_VraSR. 
VraR cloning and mutations in pMK4 containing the recent cloned segments. Italic underlined 
bases represent the restriction sites and mutations. 
VraSR FW 5’AGGAATTCGGTCCGATTTTAACGACAAAAATTG 
 
EcoRI 
VraSR Rev 5’CGGGATCCACGTTCAACATAGTTCATAAC 
 
BamHI 
VraR FW 5’CGGGATCCATG ACGATTAAAG TATTGTTTG 
 
BamHI 
VraR Rev 5’GCGTCGACCTA TTG AAT TAA ATT ATG TTG 
 
SalI 
 
S164A FW 5’GATTGCGAAAGGTTACGCAAATCAAGAAATTGCTAG 
 
- 
 
S164A Rev 5’CTAGCAATTTCTTGATTTGCGTAACCTTTCGCAATC - 
M13A FW 5’GTGGATGATCATGAAGCGGTACGTATAG 
- 
M13A Rev 5’CTATACGTACCGCTTCATGATCATCCAC - 
S164PFW 
5’GATTGCGAAAGGTTACCCAAATCAAGAAATTGCTAG
TGC 
- 
 
S164P Rev 
5’GCACTAGCAATTTCTTGATTTGGGTAACCTTTCGCA
ATC 
 
- 
E59D FW 5’GATTTACTTATGGACGACATGGATGGTG - 
E59D Rev 5’CACCATCCATGTCGTCCATAAGTAAATC      - 
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2.2.10 q-RT-PCR to investigate the level of VraR regulon genes in S. aureus  RN4220 
and its mutant strains 
 
High Capacity RNA-to-cDNA kit (Life Technologies) was used to synthesize cDNA 
from 500ng of DNase-I treated RNA. 16sRNA gene was used as an internal control using 
designed primers: Dir 5’GCTAAGTGTTAGGGGGTTTCC and Rev 
5’TTCAACCTTGCGGTCGTACT. The 20 µl reactions were prepared consisting of 25 ng of 
cDNA, 0.25 µM of each primer (accordingly designed to target specific gene, Table 2.3), and 
10µl of SYBRE SELECT Master Mix (Life Technologies). PCR conditions were done by a 
Rotor-gene Q qRT-PCR cycler (Qiagen) as follows: First hold: 2 min at 50 °C, second 
hold:10 min for 95 °C, 40 cycles of  95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 min; 
and 72 °C for 10 min as a final extension step. 
2.2.11 MIC of RN4220, ΔVraR and ΔVraR complemented wild type and mutant 
strains 
A 96-well microliter plate with 200 µl culture volume was used to determine 
vancomycin Minimum Inhibitory Concentration (MIC). In the presence of pMK4 plasmid, 
10 µg/ml chloramphenicol were added to the TSB media. Overnight seed cultures (450 µl) 
were grown in TSB (50 ml) at 37°C, 200 rpm and the OD600nm was recorded and adjusted to 
0.05. Cells were grown in 50 ml TSB at 37 °C to achieve the OD of approximately 0.5. At 
this step a serial dilutions were done to obtain the final inoculum concentration close to 5 x 
105 CFU/ml. First, the suspension was diluted 1:10 in TSB and then this step was repeated to 
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get 100 folds dilution in total. Then, 100 µl of the final dilution were used to inoculate all the 
wells containing 2-fold of vancomycin. Plates were incubated at 37°C for 24 and 48h 
without any shaking and OD600nm was measured by Synergy H4 plate reader (BioTek). 
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2.3 Results  
2.3.1 Purification of VraR by FPLC 
VraR wild type and mutants were purified using the DEAE- Sepharose and 
Heparin-Sepharose columns. Each protein was eluted from DEAE column around 20-
30% of the linear gradient of the elution buffer (Figure 2.2a), and was eluted from the 
Heparin column around 55-60% (Figure 2.2b).          
  
 
 
  
 
 
 
Protein absorbance 
λ 280nm  
Elution buffer (%)  VraR peak 
a 
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Figure 2. 2 FPLC UV (280nm)-chromatogram showing protein eluted from purification 
columns.  
(a) FPLC UV (280nm)-chromatogram showing protein eluted from DEAE column. VraR 
wild type and mutants are eluted around 40-60% gradient of elution buffer (500mM Tris pH 
7.0, and 5 mM MgCl2). (b) Chromatogram showing protein eluted from Heparin column. 
VraR wild type and mutants are eluted around 40-60% gradient of elution buffer. Y axis: 
Elution buffer content (%); X axis: Order numbers of collection tubes; The blue and green 
lines are representing protein absorbance λ 280nm and content of elution buffer (%). 
 
2.3.2 CD & thermal melting 
CD technique was used to help us defining a protein structure-folding pattern. This 
method showed that a protein is correctly folded, miss-folded or denatured. According to 
Protein absorbance λ 
280nm  
Elution buffer (%).  
VraR Peak 
b 
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the circular dichroism spectra, VraR wild type and mutants showed similar CD patterns 
with large amount of beta-sheets. Therefore, by overlapping all the spectra, it was indicated 
that all proteins possessed identical secondary structures (Figure 2.3). 
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Figure 2. 3 Circular dichroism Spectra of VraR wild type and mutants (M13A, E59D, 
S164P, S164A, and A113V).  
(a) VraR WT and M13A (10 µM) spectra in an equilibration buffer (20mM Tris, 5mM 
MgCl2, pH 7.0) was acquired at 22°C. (b) Spectra represents VraR WT and the rest of the 
mutants (S164P, A113V, S164A, and E59D). 
 
 
Thermal melting was performed to provide more information about proteins 
potential stability and to compare the effects of mutation on them. For this purpose the 
temperature dependent protein denaturation was monitored using Circular Dichroism 
spectroscopy. Absorbance at 260nm was observed in different ranges of temperature and 
the Tm was estimated as measuring the middle point of the melting curve. In fact, the 
mutants showed the same melting point at around 50.5-60°C as wild type, which means 
mutation did not alter protein-native structure (Figure 2.4). 
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Figure 2. 4 Thermal melting analysis of VraR WT and mutants. 
(a) Thermal melting curves of VraR WT and M13A (10 µM) were obtained by monitoring 
changes in flexibility at 222nm as temperature was increased at a rate of  2°C, in the range of 
20°C -90°C. (b) Thermal melting curves of VraR WT, A113V, S164A, and E59D. 
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2.3.3 Analysis of protein phosphorylation by phos-tagTM gel electrophoresis 
VraR proteins phosphorylation estimation was done by phos-tagTM gel 
electrophoresis. The results demonstrated that the wild type VraR has the ability to accept 
the phosphoryl group but Vra M13A underwent phosphorylation at a much lesser extent in 
comparison to other mutants (Figure 2.5). However, according to the quantification results 
from two or three different trials, VraR S164A phosphorylation rate is the highest one in 
comparison to the wild type and the rest of the mutants after 30 min (Figure 2.6).  
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Figure 2. 5 Phosphorylation analysis of VraR wild type and mutants by Phos-tag gel. 
20 µM VraR was phosphorylated by 50 mM Acetyl phosphate(AP) at 37°C and quenched by 
an SDS dye in time intervals and loaded on 12.5% SDS gel containing phos-tag and 
MnCl2Lane 1: controls having no AP, Lane 2-5: quenching time intervals(a) VraR WT (b) 
VraR M13A (c) VraR E59D (d) VraRS164A (e) VraR S164P (f) VraR A113V
  f. A113V 
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2.3.4 Analyzing the oligomerization state 
Native- PAGE was performed to investigate protein’s dimerization ability after 
phospohrylation. Dr. Golemi-Kotra’s Laboratory has reported that phosphorylation induces 
dimerization of VraR. Accordingly, Native-PAGE analysis showed that under the similar 
conditions, VraR M13A did not form dimer unlike the wild type. However all other mutants 
behaved same as the wild type by forming the second band as a dimer (Figure 2.7).  
                             
                       
          
 
 Figure 2. 6 Phos-tag gelTM quantification. 
Phos-tag gel band intensities of two or three different trials were analyzed by ImageJ 
to determine percentage of phosphorylation in wild type as well as all the mutants. 
Error bars indicate standard error of mean calculated from three independent 
experiments. 
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Figure 2. 7 Dimerization analysis of non-phosphorylated (NP) and phosphorylated (P) 
VraR wild type and mutants by 10% NATIVE PAGE 
(a) VraR WT (10 µM and 20µM) and the same concentration of phospohrylated VraR WT 
by 50 mM acetyl phosphate were analyzed by 10% native gel. (b) VraR-M13A (10 µM and 
20 µM) in both P and NP versions. (c) VraR-E59D M13A (10 µM and 20µM) in both P and 
NP versions. (d) VraR-S164P (10 µM, 20, and 30µM) in both P and NP versions. (e) VraR 
S164A (10 µM, 20, and 30µM) in both P and NP versions. (f) VraR S164A (10 µM, 20, and 
30µM) in both P and NP versions. 
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2.3.5 Phosphotransfer reaction from VraS-GST to VraR  
Phosphotransfer reaction from GST-VraS to VraR in the presence of [γ-32P]- ATP 
was observed in vitro. About 70% of VraR wild type was phosphorylated by VraS within the 
first 30 second as shown by Belcheva, A., & Golemi-Kotra, D., 2008. Upon VraS 
phosphatase activity after 3 min the gradual decrease in VraR phosphorylation was observed 
that was completed after at least 10 min. Similar observations were made for the VraR 
variants, which were indicative of similar phosphorylation activity in both wild type and 
mutants, however the mutants’ de-phosphorylation other than M13A occurred faster (Figure 
2.8), (Next Page). 
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 Figure 2. 8 VraR Wild type and mutants’ phosphorylation by VraS-P in time intervals and 
their quantification graphs 
20 µM VraS was incubated by radioactive ATP (3000µCi) at RT for 1h and added to 20 µM 
VraR and quenched by an SDS loading dye 
Upper bands represent VraS autophosphorylation /dephosphorylation at the same time 
Lower bands are VraR phosphorylation by VraS 
VraS-P band intensities were measured using ImageJ software among three different trials and 
their mean percentage calculated and plotted against time versus VraR-P percentage. (a) VraR 
WT, (b) VraR M13A, (c) VraR S164P, (d) VraR E59D, (e) VraR S164A, (f) VraR A113V 
Lane1: VraS control (No VraR was added), lane2-7: time intervals that the VraS/VraR reactions 
were quenched by an SDS loading dye 
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2.3.6 DNase-I footprinting analysis 
 Previous studies on VraR DNase-I footprinting revealed that unphosphorylated 
VraR binds to a single binding site spanned from -50 to -75 (R1 region) while the 
phosphorylated one can bind to an additional site between -46 to -26 (R2 region), (Belcheva 
A. et al., 2009).  Repeating the experiment for the wild type demonstrated the same results. 
Regarding the VraR mutants, certain protected regions were observed. In case of protecting 
the DNA, some mutants behaved differently and some followed the VraR wild type pattern. 
Both unphospohrylated and phosphorylated versions of VraR M13A, which showed 
disability in dimerization, protected its promoter in a similar way to unphosphorylated wild 
type from -50 to -75 of the top DNA strand (Figure 2.9). Intensities of 3 to 4 bands in the 
protected region were measured for 3 different trials at different VraR concentrations 
utilizing ImageJ software. Subsequently, percentage of the protected DNA was plotted 
against protein concentration. According to the Figure 2.10, the M13A showed the least 
percentage of protection among all mutants. In the absence of acetyl phosphate, replacement 
of Glu-59 by Asp reduced non-phosphorylated VraR binding activity as well as its 
phosphorylated version (Figure 2.11 and Figure 2.12). A113V footprinting gel picture 
demonstrated that, due to VraR phosphorylation, there is an additional protected area, 
however, the NP-A113V protected region is approximately similar to the wild type mostly in 
the highest protein concentration (Figure 2.13 and Figure 2.14). The VraR C-terminal 
mutations (S164P and S164A) reduced the unphosphorylated protein binding activity. Both 
phosphorylated VraR S164P and S164A protected vraSR promoter at the additional R2 
region, (Figures 2.15, 2.16 and Figures 2.17, 2.18). 
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Figure 2. 9 VraR WT/M13A DNase-I fooprinting on top strand 
Lanes 1,8 are the controls having no protein, Lanes 2-7 are VraR WT having different VraR 
concentrations: Lanes 2-4 are unphosphorylated protein (5,25,and 50 uM), Lanes 5-7 are 
phosphorylated protein (5,25,and 50 uM), Lanes 9-14 are VraR M13A having different VraR 
concentrations: Lanes 9-11 are unphosphorylated VraR (5,25,and 50), lanes 12-14 are 
phosphorylated VraR (5,25,and 50) 
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Figure 2. 10 Quantification of wild type and M13A DNase I footprinting data 
Percentage of protected DNA in the region 75 to -50 is plotted against protein concentration. 
The intensity of three to four most prominent bands in the protected regions was measured 
by ImageJ software and averaged them out to calculate the protected DNA percentage. Error 
bars indicate standard error of mean calculated from three independent experiments. 
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Figure 2. 11 VraR WT/E59D DNase-I fooprinting on top strand 
Lanes 5,10, and 15 are the controls having no protein, Lanes 1-9 are VraR WT having 
different VraR concentrations: Lanes 1-4 are unphosphorylated protein (2,5,15, and 25 uM), 
Lanes 6-9 are phosphorylated protein (2,5,15, and 25 uM) , Lanes 11-19 are VraR E59D 
having different VraR concentrations: Lanes 11-14 are unphosphorylated VraR (2,5,15, and 
25 uM ), lanes 15-19 are phosphorylated VraR (2,5,15, and 25 uM) 
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Figure 2. 12 Quantification of wild type and E59D DNase I footprinting data 
Percentage of protected DNA in the region 75 to -50 is plotted against protein concentration. 
The intensity of three to four most prominent bands in the protected regions were measured 
by ImageJ software and averaged them out to calculate the protected DNA percentage. Error 
bars indicate standard error of mean calculated from three independent experiments. 
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Figure 2. 13 VraR WT/A113V DNase-I fooprinting on top strand 
Lanes 5,10 are the controls having no protein, Lanes 1-9 are VraR WT having different VraR 
concentrations: Lanes 1-4 are unphosphorylated protein (2,5,15, and 25 uM), Lanes 6-9 are 
phosphorylated protein (2,5,15, and 25 uM) , Lanes 11-19 are VraR A113V having different 
VraR concentrations: Lanes 11-14 are unphosphorylated VraR (2,5,15, and 25 uM ), lanes 
15-19 are phosphorylated VraR (2,5,15, and 25 uM) 
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Figure 2. 14 Quantification of wild type and A113V DNase I footprinting data 
Percentage of protected DNA in the region 75 to -50 is plotted against protein concentration. 
The intensity of three to four most prominent bands in the protected regions was measured 
by ImageJ software and averaged them out to calculate the protected DNA percentage. Error 
bars indicate standard error of mean calculated from three independent experiments. 
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Figure 2. 15 VraR WT/S164P DNase-I fooprinting on top strand  
Lanes 5,10, and 15 are the controls having no protein, Lanes 1-9 are VraR WT having 
different VraR concentrations: Lanes 1-4 are unphosphorylated protein (2,5,15, and 25 uM), 
Lanes 6-9 are phosphorylated protein (2,5,15, and 25 uM) , Lanes 11-19 are VraR S164P 
having different VraR concentrations: Lanes 11-14 are unphosphorylated VraR (2,5,15, and 
25 uM ), lanes 16-19 are phosphorylated VraR (2,5,15, and 25 uM) 
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Figure 2. 16 Quantification of wild type and E59D DNase I footprinting data 
Percentage of protected DNA in the region 75 to -50 is plotted against protein concentration. 
The intensity of three to four most prominent bands in the protected regions was measured 
by ImageJ software and averaged them out to calculate the protected DNA percentage. Error 
bars indicate standard error of mean calculated from three independent experiments. 
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Figure 2. 17 VraR WT/S164A DNase-I fooprinting on top strand.  
Lanes 5,10 are the controls having no protein, Lanes 1-9 are VraR WT having different VraR 
concentrations: Lanes 1-4 are unphosphorylated protein (2,5,15, and 25 uM), Lanes 6-9 are 
phosphorylated protein (2,5,15, and 25 uM) , Lanes 11-19 are VraR S164P having different 
VraR concentrations: Lanes 11-14 are unphosphorylated VraR (2,5,15, and 25 uM ), lanes 
16-18 are phosphorylated VraR (2,5,15, and 25 uM) 
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Figure 2. 18 Quantification of wild type and S164A DNase I footprinting data 
Percentage of protected DNA in the region 75 to -50 is plotted against protein concentration. 
The intensity of three to four most prominent bands in the protected regions was measured 
by ImageJ software and averaged them out to calculate the protected DNA percentage. Error 
bars indicate standard error of mean calculated from three independent experiments. 
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2.3.7 Q-RT-PCR of S.aureus RN4220 
RN4220ΔvraR strain was provided to our lab by Dr. Ambrose Cheung (Dartmouth 
College, US). Therefore, cloning of vraSR promoter and vraR gene in pMK4 and 
transforming into the S.aureus cells were done to mimic the physiological conditions 
(Figure 2.19). Furthermore, q-RT-PCR was done to investigate different genes expression 
within VraR regulon in wild type and mutant strains.  
For this section we are reporting the qualitative data only due to the non-
reproducible data achievement. In the current study, selected genes expression was 
monitored in oxacillin treated and non-treated S. aureus RN4220 ΔvraR complemented 
with VraR wild type or VraR mutants using q-RT-PCR. The expression was then compared 
to RN4220 wild type. Accordingly, the background level of fmtA expression was high in 
RN4220ΔvraR_(vraR E59D::PMK4) in the absence of oxacillin and even more higher in 
the presence of antibiotic. Similar expression was observed for RN4220ΔvraR_(vraR 
S164P::PMK4) which was higher than wild type in both treated methods. However, fmtA 
expression in RN4220ΔvraR_(vraR M13A::PMK4) was down-regulated all the time (Table 
2.3). 
The pbp2 gene expression in RN4220 strain up-regulated after oxacillin treatment 
similar to the complementary strain. RN4220ΔvraR_(vraR S164P::PMK4) demonstrated a 
slightly higher expression of pbp2 in the non-oxacillin condition while in the oxacillin 
treatment circumstance, slight down-regulation was observed. Same behaviour was 
demontrated in RN4220ΔvraR_(vraR E59D::PMK4). However, the level of pbp2 
transcription in RN4220ΔvraR_(vraR M13A::PMK4) down-regulated, and it was quite 
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similar to the wild type in the non-oxcillin condition (Table 2.4). This could confirm the in 
vitro experiment on the VraR-M13A protein that did not function properly.  
 
 
 
Table 2. 4 pbp2 expression level (in comparison to RN4220 strain) 
 
Strains/treatment types Non-OX/WT OX/WT 
RN4220ΔvraR_(vraR::pMK4)   
RN4220ΔvraR_(vraR M13A::PMK4) Same or  
RN4220ΔvraR_(vraR E59D::PMK4)   
RN4220ΔvraR_(vraR S164P::PMK4 )   
RN4220ΔvraR_(vraR S164A::PMK4 ) Same or 
 
 
 
Table 2. 3  fmtA expression (in comparison to RN4220 strain) 
Strains/treatment types Non-OX/WT OX/WT 
RN4220ΔvraR_(vraR::pMK4)   
RN4220ΔvraR_(vraR M13A::PMK4)    
RN4220ΔvraR_(vraR E59D::PMK4)  
  
RN4220ΔvraR_(vraR S164P::PMK4 )   
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Figure 2. 19 Schematic diagram showing the pMK-4 cloning inserts and restriction 
sites. vraSR promoter from -121 to +150 with respect to the transcription start site was 
ligated to the vraR gene and as a whole segment the cloning was done in pMk-4 between 
EcoRi and SalI restriction sites.  
 
2.3.8 Vancomycin MIC of RN4220 versus ΔvraR complemented strains 
The absorbance values that have been estimated by a plate reader machine are based 
on the bacterial growth with an elevated OD600 in the particular well containing a given 
antibiotic concentration. The lowest MIC value is also determined by the culture that 
showed no bacterial growth at certain antibiotic concentration. The more intense blue color 
depicted by the plate reader, the higher is the OD600 above the baseline. Thus, the distinct 
antibiotic concentration is unable to inhibit bacterial growth (data are shown in Appendix B, 
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Figure B1). 
RN4220 has an MIC between 0.5 µg/ml to 1 µg/ml towards vancomycin, whereas 
ΔvraR has an MIC of 0.25 µg/ml to 0.5 µg/ml (Table 2.5). The complement strains including 
the mutants were able to revert the MIC back to 0.5 µg/ml unlike RN4220ΔvraR_(vraR 
S164P::PMK4) which showed MIC between 0.25 µg/ml to  0.5 µg/ml (Table 2.5). Colony 
counts method on the wild type, mutant, and complementary wild type confirmed the above 
results (data have not shown).
 
Table 2. 5 Vancomycin MICs of RN4220, RN4220ΔvraR and complement 
strains. Data were collected from three different trials 
Strain 
Vancomycin MIC 
(µg/ml) 
RN4220 0.5-1 
 RN4220ΔvraR 0.25-0.5 
 RN4220ΔvraR_(vraR::PMK4) 0.5 
RN4220ΔvraR_(vraR M13A::PMK4) 0.5 
RN4220ΔvraR_(vraR E59D::PMK4) 0.5 
RN4220ΔvraR_(vraR S164P::PMK4) 0.25-0.5 
RN4220ΔvraR_(vraR S164A::PMK4) 0.5 
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2.4 Discussion 
Response regulator proteins have been proposed to be often involved in virulence 
pathway regulation, and help bacteria to escape from the host immune system. These 
proteins have also been reported as an interesting drug targets because they have no human 
homologs (Leonard P.G., et al., 2013). VraR, the transcription factor protein represents an 
attractive therapeutic target, as the VraSR TCS is vital for S. aureus resistance to any 
available antibiotics. Hence, studying VraR protein’s structure and its DNA binding 
interactions could potentially restore S. aureus sensitivity to many antibacterial agents 
where resistance has become a critical worldwide concern. Here, the goal of our study was 
to characterize the key roles of amino acid substitutions in VraR and to examine their 
possible effects on VraR signal transduction. Some of the VraR mutants that were tested in 
this study were confirmed to be clinical strains (VraR E59D, A113V, and S164P) and were 
reported to contribute to glycopeptide (Vancomycin) resistance (Yoo J.I., et al., 2013) 
VraR and its variants were successfully purified using previously described methods 
(Belcheva A, & Golemi-Kotra D, 2008). Then, they were further investigated to compare 
their biochemical nature and DNA binding abilities with wild type VraR. 
To obtain further insights about the protein structural feature, circular dichroism 
spectra was analyzed. This technique is mainly based on the fact that optically active 
biomolecules, including proteins, reveal different absorptions of left and right circularly 
polarized light within the range of 200-260nm (Mcphie P, 2001). Therefore, secondary 
structures like α-helices and β-sheets would affect the CD spectrum, producing different 
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spectra. Further, CD technique can be used to analyze protein-folding patterns helping us 
define whether a protein is correctly folded, miss-folded or denatured. In our study, it was 
shown that the wild type and the mutant proteins have similar CD spectra. Moreover, 
thermal melting was performed to provide more information about potential stability of the 
mutant (Nakanishi, K., et al., 2000). The thermal melting indicated no structural alterations 
among the wild type and the mutants. 
We used Lithium potassium acetyl phosphate in vitro as a phosphodonor molecule 
(Belcheva A, & Golemi-Kotra D., 2008), to phosphorylate VraR wild type and mutant 
proteins, to examine their phosphorylation and dimerization ability by Phos-tagTM gel and 
native-gel. It is known for almost all RRs REC domains to function as a phosphorylation-
activated switch.  REC domains exist in equilibrium between two inactive and active states. 
NMR studies indicate to a microsecond equilibrium shift fluctuation between an inactive 
unphosphorylated REC domain and stabilize phosphorylated REC domain (Gao R, & Stock 
A.M, 2009). The Regulatory domain conformational changes are the result of the 
phosphorylation, which turns the RR from an inactive OFF to an active ON state. (Birck C, 
et al., 2002). Accordingly, the M13A mutant phosphorylation rate after 45 min was 6 folds 
smaller than the wild type and it failed to form dimer.  This can be explained by this fact that 
there is a possibility that the VraR M13A switching pattern between ON and OFF is 
somehow inhibited. In other words, in the absence of this critical residue (Leonard P.G., et 
al., 2013), the active state would not be there, which may interfere with the acetyl phosphate 
dependent phosphorylation of the mutant. As an example, PhoP is a receiver domain that 
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gets stabilized and dimerized through phosphorylation (Menon S., & Wang S., 2011). 
Another study, which is performed by Rhee J.E., et al., 2008 on OmpR RR mutants indicated 
that the amino acid alteration inhibits phosphorylation in the N-terminal receiver domain. As 
a result, the M13A dimerization inability led to its failure of binding to its promoter, which 
will be discussed later. However, dimerization ability of the rest of the mutants did not get 
affected. 
VraR S164A phosphorylation rate was significantly higher compared to the wild type 
after 30 min and reached to its saturated level after 45min. This could be due to the 
experimental errors, or it could be due to the fact that alanine is a small amino acid and its 
side chain is very non-reactive and is thus hardly involved in protein functions such as 
phosphorylation (Betts M.J, et. al., 2003). Nonetheless, this mutant’s phosphorylation ability 
needs to be repeated.  
Based on the VraS structure and mathematical modeling, previous studies have 
entitled VraS as a bifunctional kinase. Bifunctional histidine kinase is able to catalyze both 
the phosphorylation and dephosphorylation of its cognate response regulator (Alves R., and 
Savageau M.A, 2003). Many HKs have the intrinsic ability to phosphorylate their cognate 
RR. In this regard Belcheva A., et al., (2008) for the first time showed that the 
phosphotransfer from GST-VraS to VraR is very efficient with about 70% of the transfer 
taking place within the first 30 seconds. This rapid phosphotransfer was observed in all the 
mutants along with the wild type as a control and suggested that in the presence of cell wall 
stress, this system could be readily activated resulting in high levels of phosphorylated VraR 
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species in cell. Consequently, the amino acid substitutions in VraR did not effect the VraS-
VraR interactions. In turn, phosphotransfer from VraS to VraR was not altered within 10 
min.  
Many RRs have an inherent skill to go through dephosphorylation, however this 
activity is gradual and is normally enhanced by the cognate HK or an auxillary protein. 
(Bilwes A.M, et al., 2000, Belcheva and Golemi-Kotra, 2008).  This phenomenon is referred 
to the phosphatase activity of HK (Laub M.T., and Goulian M., 2007). Addition of VraS to 
the VraR-P drastically enhanced the hydrolysis of the phosphor-aspartate in VraR-P, which 
led to its rapid and complete dephosphorylation. Moreover, VraR-P by acetyl phosphate 
remained stable for about 10 hours. Several other HKs, including Enzv, FixJ, and NarX were 
presented to dephosphorylate their cognate RRs (Hedda U., et al., 2014; Diensthuber R., et 
al., 2013; Bhate M., et al., 2015). Accordingly, slightly faster dephosphorylation was 
observed for all the mutants except for the VraR M13A that behaved exactly similar to the 
wild type.  
The results further showed that phosphorylation-induced dimerization of VraR and 
its variants enhanced the VraR DNA-binding affinity. DNase-I footprinting experiment was 
used to demonstrate the binding regions of VraR on the vraSR promoter or in other words 
predicting the ability of the protein in protecting its promoter regions against DNase-I attack. 
Previously, it was shown that phosphorylation has an effect on VraR conformation and 
DNA-binding activity. Accordingly most of the RRs dimerization upon phosphorylation 
leads to bring the DNA-binding domain to close proximity and bind to DNA sequences 
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(Menon S., and Wang S (2011). Thus, any factor that diminishes the phosphorylation-
induced activation, would definitely affect its DNA binding interactions. Referring to the 
example earlier about the OmpR mutant’s disability in dimerization, which negatively 
affected its DNA binding activity (Rhee J.E., et al., 2008). In current study, the M13A-P did 
not bind to the R2 phosphorylated-dependent region of its promoter. However, binding 
ability of E59D-P and A113V-P to the R2 region was slightly decreased as compared to the 
wild type. The VraR C-terminal mutations (S164A and S164P) caused a partial loss of their 
DNA binding ability in their unphosphorylated state, especially in low protein concentrations 
unlike their phosphorylated versions. 
It was explained that when vancomycin MIC of S. aueus is lowered than ≤ 2 µg/mL 
counts as susceptible (CSLI, 212). Moreover, the most prevalent amino acid substitutions 
such as the E59D and A113V were shown to being susceptible to vancomycin, with an MIC 
range from 3-4 µg/mL (Yoo J., et al., 2013). In another study, VISA strains composed of 
clinical, and in-vitro strains were defined to have an MIC between 4-8 µg/ml (Alam M.T., 
et al., 2014). The S. aureus RN4220 strain, used in this research is a susceptible strain and 
introducing only vraR or a single mutation in vraR did not convert it to a resistant strain. It 
shows that there might be some other factors involving in vancomycin resistance as well 
(Hafer C, et al., 2012). Overall, it was observed that in the absence of vraR, the MIC goes 
down and introducing the vraR takes the MIC back to the control level. That is further 
enhanced by the introduction of the M13A, E59D, S164A and S164P mutations. Current 
MIC result showed increased-sensitivity towards vancomycin, however, ΔvraR complement 
  65 
strains were able to revert the MIC back to the wild type level (0.5-1 µg/mL). As the MIC 
range is very little, but it is understood that vraSR system play a significant role in 
antibiotic resistance in S.aureus that it is better to demonstrate by an alternative method. 
The q-RT-PCR analysis of S. aureus N315 cell wall-associated genes such as pbp2, 
fmtA, and sgtB, were shown to be upregulated in response to oxacillin, (Sengupta, M., et al., 
2012). In current study, the fmtA transcription levels in the clinical strains, 
RN4220ΔvraR_(vraR S164P::PMK4) and RN4220ΔvraR_(vraR E59D::PMK4) observed 
higher compare to the wild type in both treated and non-treated conditions, unlike 
RN4220ΔvraR_(vraR M13A::PMK4). RN4220 and its complementary strain up-regulate the 
pbpb2 transcription level as expected. The lower levels of pbp2 in E59D, S164P and S164A 
compared to the wild type in the presence of oxacillin could have an impact on carbohydrate 
chains cross-linking process in cell-wall biosynthesis (Boyle-Varvara. S. et al., 2012).  It is 
definitely necessary to repeat the q-RT-PCR experiment to obtain conclusive data. Then, if 
any of the genes expression increase, the will enhance peptidoglycan biosynthesis and 
antibiotic resistance. On the other hand, the decreased level of transcription interrupts in the 
cell-wall biosynthesis process leading to the antibiotic positive effect. 
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3 CHAPTER THREE: CONCLUSIONS AND FUTURE 
PERSPECTIVE 
 
3.1 Conclusion 
The discovery of TCSs happened 30 years ago and scientists have made great strides 
toward understanding the signal transduction mechanism. Here, we discuss specifically on 
the VraSR system in S. aureus. It has been demonstrated that how the VraSR TCS 
coordinates bacterial responses to the cell wall damage by modulating a set of genes and a 
phosphorelay mechanism (Stock AM, 2009). Transcription levels of certain genes have been 
shown to enhance, in the presence of peptidoglycan inhibitors at comparatively low 
concentrations of antibacterial agents such as vancomycin (Gardete S, et al., 2006; Kuroda 
M, et al., 2003). 
VraR wild type was expressed and purified previously by Antoaneta Belcheva 
(2008) in Dr. Golemi-Kotra Laboratory. Therefore, we were able to express and purify the 
already generated mutants of vraR encoding for substitutions M13A, A113V, S164P, and 
S164A. The E59D substitution was also confirmed and the pure protein was isolated with 
the same purification method. Subsequently, to get an understanding of the role of each 
substitution in VraR; biochemical properties, folding pattern, potential stability of each 
protein was analyzed. These studies did not reveal a significant diffrence amoung the 
secondary structural features of VraR and its variants.  
To illustrate oligomerization state and phosphorylation ability of the proteins in 
vitro the native gel analysis and the phos-tag gelTM were carried out. The phos-tagTM gel 
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experiment displayed the least phosphorylation rate for M13A compared to the wild type due 
to the inactive/active equilibrium shift (Birck C, et al., 2002). Other vraR variants showed 
phosphorylation contents between 70%-80% after 45 min similar to the wild type. 
However, after 30 min, higher phosphorylation content was observed for VraR-S164A. So, it 
will be necessary that this experiment repeat for further conclusive explanation. Belcheva et 
al., (2008) indicated the VraR wild type dimerization ability upon phosphorylation 
previously. The native-page gel analysis determined similar behavior between wild type and 
mutants in dimerization ability except for VraR-M13A. The effect of Met-13 point 
mutation to Ala on VraR dimerization ability without any significant alterations on its 
biochemical properties, made us realize that it is essential to examine the DNA binding 
ability. 
The VraS and VraR relationship in exchanging phosphoryl group was done by the 
radioactive [γ-32P]-ATP. Earlier, our lab indicated that the wild type VraR-dependent 
phospohtrasfer is fast and about 70% of it occurs within 30 seconds (Belcheva A., & Golemi-
Kotra D, 2008). Current research illustrated that the amino acid replacements did not alter 
VraR phosphorylation by VraS. 
Identification of the VraR binding sites on its promoter was performed by DNase-I 
footprinting to point out the VraR binding activity (Belcheva A, et.al., 2012). The M13A 
substitution caused a complete loss of the VraR-P binding affinity at R2, which was in 
agreement with its dimerization disability. The loss of binding definitely has an impact on 
the expression of the related genes regulation in the stress condition. In all mutants the non-
phosphorylated proteins protected their DNA in much lesser extent than the wild type, 
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which of VraR S164A, S164P, and E59D are the least ones. The rest of the phosphorylated 
mutants protected the R2 region but in a slight lower level than the wild type. Nonetheless, 
in this study, the VraR amino acid manipulations, slightly reduced or disabled proteins’ 
binding affinity to their DNA. 
According to the in vivo studies, vraSR promoter and vraR gene were cloned into 
pMK-4 properly, and RN4220 transformation mimicked physiological conditions to 
examine q-RT-PCR analysis and vancomycin minimum inhibitory concentrations.  
q-RT-PCR was used for certain cell-wall-associate genes known to be upregulated 
under oxacillin treatment (Sengupta, M, et al., 2012). We demonstrated qualitative 
outcomes due to the non-reproducible data, and compared each strain within its category 
along with the wild type control: antibiotic treatments versus RN4220-wild type and non-
antibiotic treatments versus RN4220-wild type. This experiment needs further analysis in 
order to achieve conclusive and quantitative data. 
MICs of the susceptible strains showed the ability of complementary strains to bring 
the MIC back to the wild type (RN4220) unlike the RN4220ΔvraR. Because of the small 
range of MIC concentration, it is still necessary to confirm the effect of mutations in an 
alternative way. 
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3.2 Future perspective 
The observation that the VraR-M13A does not form any dimers upon 
phosphorylation and loses its binding ability to the R2 region is certainly an interesting one. 
We have provided solid evidence that this mutation inhibits the expected VraR role as a 
transcription factor. Also, it is remarkable that the mRNA level of this mutant’s cell-wall-
associated genes was downregulated in both oxacillin and non-oxacillin conditions. 
Thereupon, it is also worth to examine the cell-wall-associated genes expression under 
vancomycin introduction not only in this complementary strain but also in all the mutated 
complement strains. Consequently, we will be able to be more conclusive about the current 
in vivo studies. Future work can also focus on the effect of these amino acid alterations on 
the cell growth pattern by subjecting the antibiotics. 
It is also interesting to find any other key residues in the VraR protein, and by doing 
multiple mutations at a time, analyze any possible outcomes, from their structural stability 
to the promoter protection ability. VraR-A113V mutant, a clinical S. aueus strain, still 
needs to be studied in vivo using q-RT-PCR and MIC. 
I am also interested in to observe the consequences of the VraT and VraR mutation 
simultaneously. It has been shown that VraT has an inhibitory element on LiaR protein in 
B. subtilis, the VraR homolog (Boyle-Varvara. S. et al., 2012). So, what would be the 
effects of the VraT /VraR amino acid changes on the VraSR system. 
At last, it is necessary to put more efforts and researches towards understanding the 
VraSR two-component system. Therefore, it may make us closer to our ultimate goal, 
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producing effective antibacterial agents against S. aureus resistance strains. 
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Figure A1. The VraR wild type sequence and the DNA-sequencing blast result 
of VraR-E59D mutant. The highlighted red box represents the mutated bases. 
ATGACGATTAAAGTATTGTTTGTGGATGATCATGAAATGGTACGTATAGGAATTTCAAGTTATC
TATCAACGCAAAGTGATATTGAAGTAGTTGGTGAAGGCGCTTCTGGTAAAGAAGCAATTGCCA
AAGCCCATGAGTTGAAGCCAGATTTAATTTTAATGGATTTACTTATGGAAGACATGGATGGTGT
AGAAGCGACGACTCAGATTAAAAAAGATTTACCGCAAATTAAAGTATTAATGTTAACTAGTTT
TATTGAAGATAAAGAGGTATATCGTGCATTAGATGCAGGTGTCGATAGTTACATTTTAAAAAC
AACAAGTGCAAAAGATATCGCCGATGCAGTTCGTAAAACTTCTAGAGGAGAATCTGTTTTTGA
ACCGGAAGTTTTAGTGAAAATGCGTAACCGTATGAAAAAGCGCGCAGAGTTATATGAAATGCT
TACAGAACGAGAAATGGAAATATTATTATTGATGCGAAAGGTTACTCAAATCAAGAAATTGCT
AGTGCATCGCATATTACTATTAAAACGGTTAAGACACATGTGAGTAACATTTTAAGTAAGTTAG
AAGTGCAAGATAGAACACAAGCTGTCATCTATGCATTCCAACATAATTTAATTCAATAG 
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Figure B1 Raw data from vancomycin MIC experiment. The darker the box the higher is 
the OD600. 
 
 Strains/ Vancomycin (µM) 2 1 0.5 0.25 0.125 0 
 
RN4220 
 
0.051 0.048 1.16 1.066 1.045 1.242 
 
RN4220 
 
0.047 1.309 1.461 1.493 1.517 1.457 
 
RN4220ΔVraR 
 
0.045 0.046 0.046 1.573 1.368 1.552 
 
RN4220ΔVraR_(vraR::PMK4) 
 
0.045 0.045 1.156 1.325 1.158 1.386 
 
RN4220ΔVraR_(vraR 
M13A::PMK4) 
 
0.053 0.047 0.613 0.886 1.196 1.184 
 
RN4220ΔVraR_(vraR 
E59D::PMK4) 
 
0.047 0.046 0.757 1.188 1.522 1.432 
 
RN4220ΔVraR_(vraR 
S164P::PMK4) 
 
0.049 0.048 0.049 0.953 1.317 1.333 
 
RN4220ΔVraR_(vraR 
S164A::PMK4) 
 
0.049 0.046 0.651 1.217 1.241 1.357    
